Standard
Bone Status in Obese, Non-diabetic, Antipsychotic-Treated Patients, and Effects of the Glucagon-Like Peptide-1 Receptor Agonist Exenatide on Bone Turnover Markers and Bone Mineral Density. / Eriksson, Robert; Broberg, Brian V.; Ishoy, Pelle L.; Bak, Nikolaj; Andersen, Ulrik B.; Jorgensen, Niklas R.; Knop, Filip K.; Ebdrup, Bjørn H.
In:
Frontiers in Psychiatry, Vol. 9, 781, 2019.
Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
Eriksson, R, Broberg, BV, Ishoy, PL, Bak, N, Andersen, UB, Jorgensen, NR
, Knop, FK & Ebdrup, BH 2019, '
Bone Status in Obese, Non-diabetic, Antipsychotic-Treated Patients, and Effects of the Glucagon-Like Peptide-1 Receptor Agonist Exenatide on Bone Turnover Markers and Bone Mineral Density',
Frontiers in Psychiatry, vol. 9, 781.
https://doi.org/10.3389/fpsyt.2018.00781APA
Eriksson, R., Broberg, B. V., Ishoy, P. L., Bak, N., Andersen, U. B., Jorgensen, N. R.
, Knop, F. K., & Ebdrup, B. H. (2019).
Bone Status in Obese, Non-diabetic, Antipsychotic-Treated Patients, and Effects of the Glucagon-Like Peptide-1 Receptor Agonist Exenatide on Bone Turnover Markers and Bone Mineral Density.
Frontiers in Psychiatry,
9, [781].
https://doi.org/10.3389/fpsyt.2018.00781Vancouver
Eriksson R, Broberg BV, Ishoy PL, Bak N, Andersen UB, Jorgensen NR et al.
Bone Status in Obese, Non-diabetic, Antipsychotic-Treated Patients, and Effects of the Glucagon-Like Peptide-1 Receptor Agonist Exenatide on Bone Turnover Markers and Bone Mineral Density.
Frontiers in Psychiatry. 2019;9. 781.
https://doi.org/10.3389/fpsyt.2018.00781Author
Eriksson, Robert ; Broberg, Brian V. ; Ishoy, Pelle L. ; Bak, Nikolaj ; Andersen, Ulrik B. ; Jorgensen, Niklas R. ; Knop, Filip K. ; Ebdrup, Bjørn H. / Bone Status in Obese, Non-diabetic, Antipsychotic-Treated Patients, and Effects of the Glucagon-Like Peptide-1 Receptor Agonist Exenatide on Bone Turnover Markers and Bone Mineral Density. In: Frontiers in Psychiatry. 2019 ; Vol. 9.
Bibtex
@article{18be0390446940a3a248f7f01adbe867,
title = "Bone Status in Obese, Non-diabetic, Antipsychotic-Treated Patients, and Effects of the Glucagon-Like Peptide-1 Receptor Agonist Exenatide on Bone Turnover Markers and Bone Mineral Density",
keywords = "exenatide, procollagen type I N-terminal propeptide (PINP), C-terminal cross-linking telopeptide of type I collagen (CTX), bone mineral density, randomized controlled trial",
author = "Robert Eriksson and Broberg, {Brian V.} and Ishoy, {Pelle L.} and Nikolaj Bak and Andersen, {Ulrik B.} and Jorgensen, {Niklas R.} and Knop, {Filip K.} and Ebdrup, {Bj{\o}rn H.}",
year = "2019",
doi = "10.3389/fpsyt.2018.00781",
language = "English",
volume = "9",
journal = "Frontiers in Psychiatry",
issn = "1664-0640",
publisher = "Frontiers Research Foundation",
}
RIS
TY - JOUR
T1 - Bone Status in Obese, Non-diabetic, Antipsychotic-Treated Patients, and Effects of the Glucagon-Like Peptide-1 Receptor Agonist Exenatide on Bone Turnover Markers and Bone Mineral Density
AU - Eriksson, Robert
AU - Broberg, Brian V.
AU - Ishoy, Pelle L.
AU - Bak, Nikolaj
AU - Andersen, Ulrik B.
AU - Jorgensen, Niklas R.
AU - Knop, Filip K.
AU - Ebdrup, Bjørn H.
PY - 2019
Y1 - 2019
KW - exenatide
KW - procollagen type I N-terminal propeptide (PINP)
KW - C-terminal cross-linking telopeptide of type I collagen (CTX)
KW - bone mineral density
KW - randomized controlled trial
U2 - 10.3389/fpsyt.2018.00781
DO - 10.3389/fpsyt.2018.00781
M3 - Journal article
C2 - 30745885
VL - 9
JO - Frontiers in Psychiatry
JF - Frontiers in Psychiatry
SN - 1664-0640
M1 - 781
ER -
